Our BEPO® technology allow us to develop long-acting treatment
Our patented BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months. At the time of the injection, the BEPO® technology forms a deposit of polymers of a few millimeters under the skin for a systemic action, or locally for a targeted action. The deposit diffuses the active ingredient by resorbing for the desired duration, like a mini pump that would be injectable and bio-resorbable.
In many indications
Once a medical need has been identified, the potential of the product validated and its technical feasibility evaluated positively, the MedinCell team creates a prototype that meets the targeted specifications, in particular the duration of action and the dose of active ingredient to be released. For each product, a new polymer combination is created, making each formulation unique and exclusive.
BEPO® is composed of a solution of diblock (DB) and triblock (TB) copolymers containing hydrophilic and water-soluble blocks (polyethylene glycol – PEG) linked with hydrophobic and amorphous blocks (Poly(D,L-lactic acid) – PLA) which precipitate in forming a depot when exposed to an aqueous environment.
The API is entrapped within the polymer matrix and is released thereafter by difusion and following polymer degradation. The hygroscopy and consequently the API release kinetics from the depots can be fine tuned by adjusting the hydrophilicity of the DB and TB and their relative ratio.
PEG (polyethylene glycol) block
- Also known as polyethylene oxide (PEO)
- Commercially available over a wide range of MW
- Hydrophilic, water soluble
- PLA block
- Poly (D,L-lactic acid) or poly (D,L-lactide)
- Prepared by polymerization (ROP) of cyclic (D,L)-lactide monomer
- Amorphous, hydrophobic
- Biodegradable macromolecule (through hydrolysis)
Diblock Copolymers (DB)
Triblock Copolymers (TB)
Scientific & Technical
December 12, 2021
Intra-articular delivery of full-length antibodies through the use of an in situ forming depot
August 10, 2021
Impact of octreotide counterion nature on the long-term stability and release kinetics from an in situ forming depot technology
June 04, 2021
Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model
April 22, 2021
Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Copolymers for the Formulation of In Situ Forming Depot Long-Acting Injectables
March 06, 2021
Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Amphiphilic Copolymers for Long-Acting Injectables: Synthesis, Non-Acylating Performance and In Vivo Degradation
May 18, 2020
Effects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle
March 10, 2020
BEPO®: Bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG- PDLLA based in situ forming depots with flexible drug delivery kinetics modulation
September 20, 2018